David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs

22 Apr, 2021

David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs
Photo by Sarah Shaffer on Unsplash

– Maxwell Biosciences has secured a major investment from well-known pharmaceutical investor-entrepreneur and public service champion — David Evans Shaw.
– The investment will be used to advance Maxwell’s CLAROMER™ brand anti-infectives program towards clinical stage development.
– CLAROMER™ brand anti-infectives destroy a broad spectrum of viruses, as shown in preclinical studies and imaging of viral structures.
– The mechanism of action of this new small molecule drug class is shown using cryo-electron microscopy imaging of treated virus structures (imaging confirmed at independent labs).
– Over a decade of published academic articles illustrate selective targeting of pathogens by Maxwell’s product candidates.

Biotechnology Health Care North America
Crunchbase icon

Content report

The following text will be sent to our editors: